In today’s cosmetics industry, data is everywhere. Instrumental measurements, clinical studies, consumer perception panels, in vitro assays, and AI-driven skin analysis—brands have more raw data at their disposal than ever before. Yet despite this abundance, many brands struggle with a fundamental issue: the inability to interpret, contextualise, and translate raw data into compliant, meaningful cosmetic claims…
The result is not just weak marketing—it is regulatory risk, consumer mistrust, and missed opportunities for innovation.
Data Abundance Does Not Equal Data Understanding
Modern cosmetic development generates layers of data at every stage:
- Raw instrumental outputs (corneometry, TEWL, profilometry, colourimetry)
- Statistical outputs from clinical studies
- Supplier-provided efficacy summaries
- Consumer self-assessment questionnaires
- Digital and AI-derived skin metrics
However, raw data is not a claim. It is simply information—often incomplete, context-dependent, and easily misinterpreted when removed from its original experimental framework.
Many brands assume that data alone justifies a claim. In reality, claims require:
- Scientific relevance
- Proper statistical treatment
- Methodological transparency
- Alignment with regulatory definitions
Without these elements, data becomes a liability rather than an asset.
The “Telephone Game” Between R&D and Marketing
One of the most common failure points occurs during handover between departments. Raw or semi-interpreted data often moves from R&D to marketing without sufficient explanation of what was actually measured, under what conditions, and what the data can—and cannot—support.
By the time it reaches packaging or digital content, nuanced findings are often simplified into absolute or exaggerated statements. A statistically significant change becomes a universal promise. A controlled test condition becomes a real-world expectation.
This breakdown is rarely intentional; it is structural. Many organisations lack a shared language across science, regulatory, and marketing teams, leading to claims that drift from the original data.
Supplier Data: Useful, But Not Plug-and-Play
Ingredient suppliers play a critical role in innovation, yet their data is often misunderstood or overextended. Supplier studies are typically:
- Conducted under specific formulations
- Designed to demonstrate ingredient potential, not finished-product performance
- Limited in population size or duration
Yet brands often treat supplier data as turnkey substantiation. Applying raw ingredient data directly to a finished product without reformulation validation significantly weakens the scientific link. Understanding what supplier data represents—and where its limitations lie—is essential for responsible claim development.
Statistics Without Context: A Growing Problem
Another common issue is the misuse of statistical significance. A “statistically significant improvement” does not automatically imply clinical relevance, a benefit that consumers can perceive, or long-term efficacy. Brands increasingly cite percentages without explaining the baseline values, the variability of the data, the duration of the study, or the relevance of the population studied. When numbers are stripped of context, they may look impressive, but they fail to withstand regulatory or expert scrutiny.
Regulatory Frameworks Demand Interpretation, Not Just Evidence
Regulatory bodies worldwide are not only asking whether brands have data but also whether they understand it. Claim substantiation requires a clear link between the test method and the claim wording, appropriate extrapolation (or the absence of it), honest representation of outcomes, and reproducibility and transparency. Misinterpreting raw data can lead to misleading claims and thus misinformation, even when they are technically “based on a study.” This distinction is increasingly important as regulators and consumers become more scientifically literate.
The Cost of Poor Data Translation
Failing to properly manage and interpret raw data leads to challenges, including reformulating claims, delays in product launches, loss of credibility with informed consumers, internal inefficiencies, and repeated testing. More critically, it restricts brands from fully harnessing the innovative potential of their datasets.
Toward Better Claim Intelligence
The solution is not more data per se, but better data intelligence. Brands that succeed are those that involve claim strategy early in study design, foster collaboration between R&D, regulatory, and marketing teams, invest in scientific literacy beyond the laboratory, and treat data interpretation as a core competency rather than an afterthought. In an industry built on trust, performance, and perception, how data is understood may matter more than how much of it exists.
Raw data is only the beginning. Insight is what turns it into a credible claim.
Read also: The Science–Claims Dilemma: Why Cosmetic Brands Struggle to Translate Data into EU-Compliant Claims, in the January/February 2026 edition of EURO COSMETICS Magazine.
